A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus

Table 1 Classification of GLP-1 RAs based on different parameters [13]

Parameter	Classification	Compound
Classification based on duration of action	Short acting (half-life < 12 h)	Exenatide Lixisenatide
	Intermediate acting (half-life 12–24 h)	Liraglutide
	Long acting (half-life 24 h to 1 month)	Exenatide LAR Albiglutide Semaglutide Orally administered semaglutide
	Continuous acting (half-life > 1 month)	ITCA 650
Based on structure	Exendin-based therapy	Exenatide Exenatide LAR Lixisenatide
Based on structure	Human GLP-1-based therapy	Liraglutide Dulaglutide Semaglutide Orally administered semaglutide
Based on mode of delivery	Subcutaneous injection	Exenatide Exenatide LAR Albiglutide Lixisenatide Liraglutide Semaglutide
	Subcutaneous implant	ITCA 650
	Oral ingestion	Orally administered semaglutide